Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Detection method of molecular marker of diffuse large B-cell lymphoma and application thereof

A molecular marker, B cell technology, applied in the fields of biology and medical testing, can solve the problems of high cost, incomplete typing results, inconsistent protein expression levels and gene expression levels, etc., to achieve similar detection results and considerable application. Prospect, good repeatability

Active Publication Date: 2012-12-05
HANGZHOU CANHELP GENOMICS TECH CO LTD
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the cost of using gene chips to detect hundreds of genes is very expensive, and the quality requirements of specimens are also high, which cannot be widely used in clinical routine laboratories
Although TMA and IHC methods can obtain some information similar to the gene expression profile at the protein expression level, the protein expression level in the body is often inconsistent with the gene expression level, making the results based on immunophenotyping and gene expression profile typing difficult. The results do not quite match
The above factors limit the translation of the research results of DLBCL molecular typing to the clinic

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Detection method of molecular marker of diffuse large B-cell lymphoma and application thereof
  • Detection method of molecular marker of diffuse large B-cell lymphoma and application thereof
  • Detection method of molecular marker of diffuse large B-cell lymphoma and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0047] Example 1. Application of LIMD1: MYBL1 indicators in DLBCL patients receiving CHOP-like chemotherapy regimens

[0048] In this example, the inventors used bioinformatics technology to extract the expression levels of LIMD1 and MYBL1 genes in 74 cases of ABC type and 76 cases of GCB type patients receiving CHOP treatment. LIMD1 gene was highly expressed in ABC type patients and lowly expressed in GCB type patients, with statistical difference, t test Pfigure 1 ). Correspondingly, MYBL1 gene was lowly expressed in ABC type patients and highly expressed in GCB type patients, which also had a statistical difference, t test P figure 2 ). The ratio of LIMD1 and MYBL1 expression (LIMD1:MYBL1 index) was further calculated, and compared with the gold standard of gene chip expression profile typing, the ROC curve of LIMD1:MYBL1 index was obtained ( image 3 ). Depend on image 3 It can be seen that the AUC of the LIMD1:MYBL1 indicator ROC curve is 0.95, which shows that the in...

Embodiment 2

[0049] Example 2. Application of LIMD1: MYBL1 indicators in DLBCL patients receiving R-CHOP chemotherapy regimen

[0050]Existing studies have confirmed that the R-CHOP regimen can significantly improve the curative effect of both GCB and non-GCB patients. In this example, the inventors used bioinformatics technology to extract the expression levels of LIMD1 and MYBL1 genes in 93 cases of ABC type and 107 cases of GCB type patients receiving R-CHOP treatment. The expression of LIMD1 gene was up-regulated in patients with ABC type and down-regulated in patients with GCB type, with statistical difference, t test P Figure 5 ); the expression of MYBL1 gene was down-regulated in patients with ABC type and up-regulated in patients with GCB type, which also had a statistical difference, t test P Image 6 ). Comparing the expression levels of LIMD1 and MYBL1, if the expression of MYBL1 is higher than that of LIMD1 (LIMD1:MYBL11), it indicates that the patient is The patient is ABC typ...

Embodiment 3

[0051] Example 3. LIMD1: Application of MYBL1 Prognostic Index in Type3-DLBCL Patients

[0052] Type3-DLBCL does not specifically express the characteristic genes of germinal center B cells and activated peripheral blood B cells, so it does not belong to GCB type or ABC type. Some scholars collectively refer to the third type and the ABC type as the non-GCB type. The gene chip expression profiling method cannot effectively classify this type of DLBCL. In this example, 64 Type3-DLBCL patients were used as an independent research cohort to evaluate the utility of LIMD1:MYBL1 indicators in such patients.

[0053] Among all patients, 31 received CHOP-like regimen and 33 received R-CHOP regimen. The inventors used bioinformatics technology to compare the expression levels of LIMD1 and MYBL1 genes, and obtained the LIMD1:MYBL1 index. If LIMD1:MYBL11, patients are classified into high-risk group (similar to ABC type). The Kaplan-Meier method was used to analyze the relationship b...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the field of biological and medical examination, and relates to a detection method of a molecular tying marker of a diffuse large B-cell lymphoma, and a kit related to the detection method. The invention firstly provides the detection method of the molecular marker of the diffuse large B-cell lymphoma, which comprises the steps as follows: 1) a biomacromolecule combined with the specificity of the molecular marker is contacted with a biological sample taken from a diffuse large B-cell lymphoma patient; 2) the expression level of the molecular marker in the biological sample is determined; and 3) a judgment model is established according to a detection result of the molecular marker. The invention further provides the application of the method to molecular tying of the diffuse large B-cell lymphoma, and the corresponding kit. The method provided by the invention can be used for judging a molecular subtype of the diffuse large B-cell lymphoma, estimating the prognosis of the patient and providing a basis for early intervention treatment and the implementation of individualized treatment.

Description

technical field [0001] The invention belongs to the field of biology and medical examination, and relates to a group of tumor molecular markers and their clinical application. Specifically, it relates to a molecular typing marker of diffuse large B-cell lymphoma, a detection method and a kit related to the detection method. Background technique [0002] Diffuse Large B-Cell Lymphoma (DLBCL) is currently the most common adult non-Hodgkin's lymphoma, and it is a highly aggressive and rapidly growing tumor. Accounts for 30% to 40% of non-Hodgkin's lymphoma in adults in Western countries 1 . At present, the incidence of non-Hodgkin's lymphoma in my country is about 4 / 100,000, and it is increasing at a rate of 2-3% per year. Among them, DLBCL is the most common, accounting for about 50% of all lymphomas every year. Therefore, every year The number of new cases nationwide is about 20,000-30,000. The 2008 WHO classification defines DLBCL as: large neoplastic B lymphocytes showin...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12Q1/68G01N33/68
Inventor 杜祥徐清华周晓燕倪淑娟谭聪
Owner HANGZHOU CANHELP GENOMICS TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com